Cattaneo M, Tenconi P M, Alberca I, Garcia V V, Mannucci P M
A. Bianchi Bonomi Hemophilia and Thrombosis Center, Maggiore Hospital, Milano, Italy.
Thromb Haemost. 1990 Nov 30;64(3):358-60.
The intravenous infusion of 1-deamino-8-D-arginine vasopressin (DDAVP) shortens the prolonged bleeding time in patients with congenital or acquired bleeding disorders, including patients with uremia or liver cirrhosis. We carried out a double-blind, placebo-controlled crossover study in ten patients with liver cirrhosis to evaluate whether or not their prolonged bleeding times could be shortened by subcutaneous injections of DDAVP (0.3 microgram/kg), a more practical route of administration than intravenous infusions. One hour after DDAVP injection the bleeding time was significantly shortened (p less than 0.05). After 4 h, however, the bleeding time shortening was no longer statistically significant. There was no bleeding time change after placebo. Plasma levels of von Willebrand factor antigen (vWF:Ag) did not significantly increase after DDAVP or placebo. The study shows that subcutaneous DDAVP is an alternative method for short-term shortening of the bleeding time in liver cirrhosis.
静脉输注1-去氨基-8-D-精氨酸加压素（DDAVP）可缩短先天性或获得性出血性疾病患者延长的出血时间，这些疾病包括尿毒症或肝硬化患者。我们对10例肝硬化患者进行了一项双盲、安慰剂对照的交叉研究，以评估皮下注射DDAVP（0.3微克/千克）是否能缩短他们延长的出血时间，皮下注射是一种比静脉输注更实用的给药途径。注射DDAVP 1小时后，出血时间显著缩短（p<0.05）。然而，4小时后，出血时间的缩短不再具有统计学意义。注射安慰剂后出血时间无变化。DDAVP或安慰剂注射后，血管性血友病因子抗原（vWF:Ag）的血浆水平均未显著升高。该研究表明，皮下注射DDAVP是短期内缩短肝硬化患者出血时间的一种替代方法。
